{
    "id": "58401470",
    "text": "Doravirine/lamivudine/tenofovir (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS. It contains doravirine, lamivudine, and tenofovir disoproxil. In the United States, in August 2018, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection. ==References== ==External links== * * * * * Category:Fixed dose combination (antiretroviral) Category:Reverse transcriptase inhibitors Category:Merck & Co. brands ",
    "title": "Doravirine/lamivudine/tenofovir"
}